Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Gilead Sciences, Inc. (NASDAQ: GILD) closed at $65.27 down -2.70% from its previous closing price of $67.08. In other words, the price has decreased by -$2.70 from its previous closing price. On the day, 15.13 million shares were traded. GILD stock price reached its highest trading level at $67.8999 during the session, while it also had its lowest trading level at $65.09.
Ratios:
For a deeper understanding of Gilead Sciences, Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.97. For the most recent quarter (mrq), Quick Ratio is recorded 1.27 and its Current Ratio is at 1.43. In the meantime, Its Debt-to-Equity ratio is 1.12 whereas as Long-Term Debt/Eq ratio is at 1.04.
On February 22, 2024, Truist Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $91 to $82.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $75.Deutsche Bank initiated its Hold rating on November 09, 2023, with a $75 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 02 ’24 when GILEAD SCIENCES, INC. bought 485,250 shares for $0.76 per share. The transaction valued at 368,790 led to the insider holds 7,345,473 shares of the business.
Parsey Merdad sold 2,000 shares of GILD for $145,920 on Apr 01 ’24. The Chief Medical Officer now owns 96,304 shares after completing the transaction at $72.96 per share. On Feb 29 ’24, another insider, Parsey Merdad, who serves as the Chief Medical Officer of the company, sold 8,230 shares for $72.74 each. As a result, the insider received 598,624 and left with 92,706 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 83646758912 and an Enterprise Value of 98535710720. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.49, and their Forward P/E ratio for the next fiscal year is 8.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.70. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.01 while its Price-to-Book (P/B) ratio in mrq is 3.56. Its current Enterprise Value per Revenue stands at 3.634 whereas that against EBITDA is 7.886.
Stock Price History:
Over the past 52 weeks, GILD has reached a high of $87.86, while it has fallen to a 52-week low of $65.90. The 50-Day Moving Average of the stock is -8.84%, while the 200-Day Moving Average is calculated to be -14.65%.
Shares Statistics:
For the past three months, GILD has traded an average of 7.21M shares per day and 7526310 over the past ten days. A total of 1.25B shares are outstanding, with a floating share count of 1.25B. Insiders hold about 0.10% of the company’s shares, while institutions hold 85.82% stake in the company. Shares short for GILD as of 1713139200 were 21182130 with a Short Ratio of 2.94, compared to 1710460800 on 19247863. Therefore, it implies a Short% of Shares Outstanding of 21182130 and a Short% of Float of 1.7000000000000002.
Dividends & Splits
According to the company, the forward annual dividend rate for GILD is 3.02, from 3.0 in the trailing year. Against a Trailing Annual Dividend Yield of 0.044722717The stock’s 5-year Average Dividend Yield is 3.98.
